pharma · Diabetes Mellitus · Hemophilia A
Takeda
NovaPharmaNews editorial coverage mentioning Takeda — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 1993
- Employees
- 1,617
- Programs
- 1179
- Drugs
- 359
- Patents
- 1436
News & analysis
NovaPharmaNews articles mentioning Takeda — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Takeda — regulatory, clinical, and market analysis.
Takeda TYK2 drug tops Bristol Myers’ Sotyktu in psoriasis head-to-head test
Takeda’s TYK2 inhibitor zasocitinib outperformed Bristol Myers Squibb’s Sotyktu in a head-to-head plaque psoriasis trial. The result strengthens Takeda’s dermatology story and gives BD teams and investors a clearer read on the program’s competitive position.
Merck-Kelun ADC's Strategic Wins and Takeda's Antitrust Loss
This article delves into Merck-Kelun ADC's recent achievements in China and the implications of Takeda's significant antitrust loss, providing strategic insights for business development teams and investors.
Takeda and Novartis Layoffs: Implications for Pharma Industry
Takeda announces a reduction of 4,500 jobs while Novartis lays off biomedical research staff. This article explores the implications for the pharma sector.
Takeda's $885M Verdict: Implications for Pharma Business Strategies
Takeda faces an $885M verdict in a pay-for-delay antitrust case, raising significant questions for pharmaceutical business strategies and market dynamics.
Takeda Settles Kickback Allegations: What It Means for Pharma
Takeda has agreed to a $13.6 million settlement regarding allegations of kickbacks to doctors. This article explores the implications for the pharmaceutical sector.
Biotech Leaders Push for Pazdur Amid Takeda Layoffs
Biotech leaders are rallying for Pazdur's approval while Takeda announces significant layoffs. This article explores the implications for the pharma industry.
Fierce Pharma Asia: Major Developments in Oncology and Workforce Changes
This article covers significant developments in the pharmaceutical sector, including BMS's $15B deal with Hengrui, Takeda's workforce reductions, and Daiichi's oncology initiatives.